CV Sciences Q1 2023 Earnings Report $0.04 +0.00 (+2.01%) As of 01/3/2025 05:40 PM Eastern Earnings History CV Sciences EPS ResultsActual EPS$0.04Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACV Sciences Revenue ResultsActual Revenue$4.15 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACV Sciences Announcement DetailsQuarterQ1 2023Date5/15/2023TimeN/AConference Call ResourcesCVSI Earnings History CV Sciences Earnings HeadlinesHemp-Focused CV Sciences Expands Via New Cannabis Acquisition, Here's What Investors Need To KnowNovember 22, 2024 | benzinga.comCV Sciences to Acquire Extract Labs in $1.4M DealNovember 21, 2024 | marketwatch.comliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the liberals broke”... But it turns out that was all just a smokescreen to hide the TRUTH…January 5, 2025 | StocksToTrade (Ad)CV Sciences, Inc. Enters Into Definitive Agreement to Acquire Extract LabsNovember 21, 2024 | prnewswire.comCV Sciences Q3: Revenue Stable Amid New Launches, FinancingNovember 15, 2024 | benzinga.comCV Sciences Reports Q3 Revenue and Product LaunchNovember 15, 2024 | markets.businessinsider.comSee More CV Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CV Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CV Sciences and other key companies, straight to your email. Email Address About CV SciencesCV Sciences (OTCMKTS:CVSI) develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.View CV Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles S&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
